; and (2) not later than 1 year after the date of enactment of this Act, submits a report on such study to the Secretary. (d) Postmarket review Not later than 2 years after the date of enactment of this Act, the Secretary, acting through the Commissioner of Food and Drugs, shall convene 1 or more meetings of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the Food and Drug Administration to review the approved labeling on all opioid drugs approved using enriched enrollment randomized withdrawal methodology under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) as of the date of the first such meeting, for the purpose of determining whether the indications on such labeling for such drugs are supported by the enriched enrollment randomized withdrawal methodology. The findings from such meetings shall be made publicly available on an internet website operated by the Secretary, acting through the Commissioner of Food and Drugs.